NCT03476330CompletedPhase 2
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid leukemia (AML) and squamous cell carcinoma (SCC). Improved transplant outcomes are modifying the natural history of Fanconi Anemia. Improved transplant survival, no radiation exposure, and almost no GVHD increases the importance of addressing later SCC even further. The investigators hypothesize that quercetin will prevent or delay the development of SCC and associated complications, there by ameliorating or delaying the need for potentially lethal treatment with chemotherapy and/or radiation therapy for the same. Funding Source - FDA Office of Orphan Products Development (OOPD)
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 19 Mar 2018
- Start date
- 8 May 2018
- Primary completion date
- 6 Mar 2025
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Diseases
- Childhood cancers
- NCT number
- NCT03476330
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 48
- From 8 May 2018 to the primary completion date, 6 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving digoxin therapy, who are unable to discontinue either treatment due to medical reasons
- Patients who have received quercetin supplementation or other antioxidants within the last 30 days
- Patients receiving radiation therapy, chemotherapy or immunotherapy for treatment of SCC.
Other illness
- Renal failure requiring dialysis
Lab values
- Total bilirubin \>3 mg/dl and/or SGPT \>200 at time of enrollment
Other
- Patients who are pregnant or breastfeeding or are at risk of pregnancy or fathering a baby and are unable to use acceptable methods of birth control during the length of the study
Who the study is looking for
- Diagnosis of FA
- Able to take enteral medication
- Patients ≥2 years
Age in the registry: 2 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cincinnati Children's Hospital Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.